Neurogene Inc.

Neurogene Inc. is a clinical-stage biotechnology company that creates genetic therapies for individuals with severe and rare neurological disorders. The company's primary focus is developing treatments using its proprietary transgene regulation platform, which controls therapeutic protein expression in targeted cells. Its leading clinical asset, NGN-401, is an adeno-associated virus gene therapy designed to treat female pediatric and adult patients suffering from Rett syndrome. The firm operates in the biopharmaceutical sector without commercialized products, directing its investigative programs toward patients and healthcare systems that manage life-threatening central nervous system illnesses.

The organization operates an internal good manufacturing practice facility measuring 42,000 square feet in Houston, Texas, which encompasses process and analytical laboratories along with 6,000 square feet of dedicated cleanroom space. It also maintains an academic research collaboration with the University of Edinburgh. The business employs 131 full-time personnel, including 106 staff members in research, development, and technical operations, with approximately 78 workers situated at the Texas production site.

Summary of the business section of Neurogene's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 16, 2026, we had 131 employees, all of whom were employed full time and 106 of whom were engaged in research, development and technical operations activities.”